Christopher B.  Ehrlich net worth and biography

Christopher Ehrlich Biography and Net Worth

Chris Ehrlich has been LWAC’s Chief Executive Officer and Director since October 2020. Mr. Ehrlich has served in various roles at Locust Walk Partners since 2013, first as Senior Managing Director and Head of Locust Walk Partners’ Global Biopharma team until 2021, and beginning in 2021 as Chief Executive Officer of Locust Walk Acquisition Corp. Prior to joining Locust Walk Partners in 2013, Mr. Ehrlich served as a Managing Director at InterWest Partners, a venture capital firm focused on healthcare and information technology, from 2000 to 2013. At InterWest, he served on the boards of KAI Pharmaceuticals, a privately held pharmaceutical company (acquired by Amgen in 2012), Biomimetic Therapeutics, Inc., a biotechnology company (acquired by Wright Medical Technologies in 2013), Invuity, Inc., a medical technology company acquired by Stryker in 2018) and Xenon Pharmaceuticals, a biopharmaceutical company (NASDAQ: XENE). Prior to joining InterWest, Mr. Ehrlich was the Director of Licensing and Business Development at Purdue Pharma, a private pharmaceutical firm, where he was responsible for developing a biologic oncology franchise, including in-licensing key intellectual properties, establishing and managing collaborations with biotechnology companies and leading the commercial operations of Purdue BioPharma, a biotechnology company. Prior to joining Purdue BioPharma, Mr. Ehrlich worked in business development at Genentech, a biotechnology company, in venture capital at the U.S. Russia Investment Fund, and in biotechnology strategy development at L.E.K. Consulting. Since 2014, Mr. Ehrlich has served on the Board of Directors of Prostate Management Diagnostics, Inc., a diagnostics company, on the Advisory Board of the Peter Michael Foundation, a charity focused on prostate cancer where he has been a Senior Advisor since 2012, and on the Healthcare at Kellogg Advisory Board at Northwestern University since 2019. He received his undergraduate degree from Dartmouth College and a MBA from the Kellogg School of Management at Northwestern University. He is also a registered representative with FINRA, holding his Series 79, 63 and 24 licenses.

What is Christopher B. Ehrlich's net worth?

The estimated net worth of Christopher B. Ehrlich is at least $20,261.12 as of October 4th, 2022. Mr. Ehrlich owns 1,408 shares of eFFECTOR Therapeutics stock worth more than $20,261 as of March 29th. This net worth approximation does not reflect any other assets that Mr. Ehrlich may own. Learn More about Christopher B. Ehrlich's net worth.

How do I contact Christopher B. Ehrlich?

The corporate mailing address for Mr. Ehrlich and other eFFECTOR Therapeutics executives is 200 CLARENDON STREET 51ST FLOOR, BOSTON MA, 02116. eFFECTOR Therapeutics can also be reached via phone at 858-925-8215. Learn More on Christopher B. Ehrlich's contact information.

Has Christopher B. Ehrlich been buying or selling shares of eFFECTOR Therapeutics?

Christopher B. Ehrlich has not been actively trading shares of eFFECTOR Therapeutics in the last ninety days. Most recently, on Tuesday, October 4th, Christopher B. Ehrlich bought 13 shares of eFFECTOR Therapeutics stock. The stock was acquired at an average cost of $14.25 per share, with a total value of $185.25. Following the completion of the transaction, the director now directly owns 1,408 shares of the company's stock, valued at $20,064. Learn More on Christopher B. Ehrlich's trading history.

Who are eFFECTOR Therapeutics' active insiders?

eFFECTOR Therapeutics' insider roster includes Christopher Ehrlich (Director), and Jonathan Root (Director). Learn More on eFFECTOR Therapeutics' active insiders.

Are insiders buying or selling shares of eFFECTOR Therapeutics?

During the last twelve months, insiders at the sold shares 1 times. They sold a total of 24,366 shares worth more than $371,581.50. The most recent insider tranaction occured on November, 27th when Major Shareholder Sr One Capital Management, Llc sold 24,366 shares worth more than $371,581.50. Insiders at eFFECTOR Therapeutics own 8.4% of the company. Learn More about insider trades at eFFECTOR Therapeutics.

Information on this page was last updated on 11/27/2023.

Christopher B. Ehrlich Insider Trading History at eFFECTOR Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/4/2022Buy13$14.25$185.251,408View SEC Filing Icon  
9/26/2022Buy754$13.75$10,367.501,394View SEC Filing Icon  
2/18/2022Buy40$107.50$4,300.00View SEC Filing Icon  
2/14/2022Buy80$111.25$8,900.00View SEC Filing Icon  
2/8/2022Buy40$123.00$4,920.00View SEC Filing Icon  
2/3/2022Buy200$128.75$25,750.00View SEC Filing Icon  
1/27/2022Buy200$132.50$26,500.00View SEC Filing Icon  
See Full Table

Christopher B. Ehrlich Buying and Selling Activity at eFFECTOR Therapeutics

This chart shows Christopher B Ehrlich's buying and selling at eFFECTOR Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

eFFECTOR Therapeutics Company Overview

eFFECTOR Therapeutics logo
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Read More

Today's Range

Now: $14.39
Low: $13.25
High: $14.72

50 Day Range

MA: $11.98
Low: $9.08
High: $16.95

2 Week Range

Now: $14.39
Low: $8.44
High: $37.00

Volume

349,809 shs

Average Volume

155,172 shs

Market Capitalization

$37.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52